In-depth guides
Focused explainers place opioid withdrawal questions beside the evidence, risks, and limits of ibogaine. Context also matters across settings, including discussion of ibogaine treatment in Colorado.
Information offerings
Services
A calm, evidence-first set of guides and reference tools for understanding ibogaine in the context of opioid withdrawal—without presenting investigational information as established care.
For people affected by opioid withdrawal, supporters, and professionals seeking clear context on evidence and risk.
A careful orientation
Information before interpretation.
Slow Ledger 29 organizes difficult material into plain-language pathways. The starting point is our overview of ibogaine and opioid withdrawal, which keeps research findings, safety questions, and regulatory limits in view together.
Our purpose is defined by the resource’s independence and evidence-first approach: help readers distinguish investigational findings from established opioid-use-disorder care, while respecting uncertainty and the seriousness of withdrawal.
What we provide
Practical routes through a complicated subject.
These are information services—not medical, legal, or treatment services. Each is designed to make the questions around ibogaine easier to locate, compare, and discuss responsibly.
Decision frameworks
Our frameworks help readers separate a compelling claim from the practical questions it raises: what is known, what remains uncertain, what safety concerns need attention, and what established care options should remain visible.
Research summaries
Short, plain-language research summaries track emerging work without overstating it. This includes items such as an Arizona study on ibogaine, PTSD, and brain injuries, whose subject differs from opioid withdrawal but illustrates why study context matters.
Comparisons and glossaries
Definitions and comparisons clarify terms that are often blurred together. The U.S. Substance Abuse and Mental Health Services Administration’s medication guidance helps ground discussion of evidence-based treatment for substance-use disorders.
Research in context
A source is not a conclusion.
Our summaries preserve the difference between early signals, development activity, and established practice. For example, support for a U.S. push toward ibogaine development is relevant to the direction of research, not proof of a clinical outcome.
The same care applies to definitions. Ibogaine’s broad reference profile can help orient a reader, but it does not replace evaluation of a study’s methods, participant group, safety procedures, or limits.
“The useful question is not whether a claim feels hopeful. It is what the available evidence can—and cannot—support.”
Common questions
Useful context, held with care.
These answers describe the scope of this resource. They do not replace a conversation with a qualified healthcare professional or emergency support when it is needed.
Are these medical services?
No. Slow Ledger 29 is an independent information resource. It does not provide diagnosis, treatment, clinical screening, or medical advice. The material is intended to support clearer questions and more careful interpretation.
Why separate investigational findings from established care?
The evidence base, legal status, and safety requirements surrounding ibogaine are distinct from established opioid-use-disorder care. That distinction is especially important when considering reports such as ibogaine treatment accounts involving Air Force pilots, which do not answer the clinical questions specific to opioid withdrawal.
Do the guides address how ibogaine is discussed outside opioid withdrawal?
Yes, where it helps clarify the limits of comparison. We may note material on topics such as ibogaine treatment for martial artists or ibogaine seeds, while keeping the focus on what is and is not relevant to the opioid-withdrawal brief.
Keep the question open
Start with the clinical evidence, then keep safety in the frame.
Use the evidence overview as a measured next step for understanding the subject without turning uncertainty into a promise.
Explore clinical evidence